OBJECTIVES: To measure the effectiveness of topical 2% dorzolamide hydrochloride (Trusopt, Merck & Co Inc, Whitehouse Station, NJ) as a suppressor of aqueous humor flow in the human eye as compared with the effectiveness of 0.5% timolol maleate (Timoptic, Merck & Co Inc) and to measure the additivity of the 2 drugs. DESIGN: A randomized, double-masked, placebo-controlled study of 40 human subjects was carried out in 2 academic centers (Mayo Clinic, Rochester, Minn, and University of Uppsala, Uppsala, Sweden). The rate of aqueous flow was measured from 8 AM to 4 PM by means of fluorophotometry after administration of doses of each drug singly and both drugs together. RESULTS:Dorzolamide reduced aqueous flow from 3.07 +/- 0.63 microL/min (mean +/- SD) to 2.53 +/- 0.60 microL/min, a reduction of 18% (P < .001). Timolol reduced aqueous flow from the same beginning rate to 1.64 +/- 0.35 microL/min, a reduction of 47% (P < .001). The inhibitory effect of timolol was 2.6 times the inhibitory effect of dorzolamide (P < .001). The 2 drugs were almost completely additive, and together reduced the flow to 1.37 +/- 0.33 microL/min, a reduction of 55%. Consistent effects were observed on intraocular pressure. CONCLUSIONS:Timolol is more effective than dorzolamide as a suppressor of aqueous humor flow in the normal human eye. Timolol and dorzolamide are additive in their effects, both on aqueous flow and intraocular pressure.
RCT Entities:
OBJECTIVES: To measure the effectiveness of topical 2% dorzolamide hydrochloride (Trusopt, Merck & Co Inc, Whitehouse Station, NJ) as a suppressor of aqueous humor flow in the human eye as compared with the effectiveness of 0.5% timolol maleate (Timoptic, Merck & Co Inc) and to measure the additivity of the 2 drugs. DESIGN: A randomized, double-masked, placebo-controlled study of 40 human subjects was carried out in 2 academic centers (Mayo Clinic, Rochester, Minn, and University of Uppsala, Uppsala, Sweden). The rate of aqueous flow was measured from 8 AM to 4 PM by means of fluorophotometry after administration of doses of each drug singly and both drugs together. RESULTS:Dorzolamide reduced aqueous flow from 3.07 +/- 0.63 microL/min (mean +/- SD) to 2.53 +/- 0.60 microL/min, a reduction of 18% (P < .001). Timolol reduced aqueous flow from the same beginning rate to 1.64 +/- 0.35 microL/min, a reduction of 47% (P < .001). The inhibitory effect of timolol was 2.6 times the inhibitory effect of dorzolamide (P < .001). The 2 drugs were almost completely additive, and together reduced the flow to 1.37 +/- 0.33 microL/min, a reduction of 55%. Consistent effects were observed on intraocular pressure. CONCLUSIONS:Timolol is more effective than dorzolamide as a suppressor of aqueous humor flow in the normal human eye. Timolol and dorzolamide are additive in their effects, both on aqueous flow and intraocular pressure.
Authors: Arash Kazemi; Jay W McLaren; Matthew G J Trese; Carol B Toris; Vikas Gulati; Shan Fan; David M Reed; Tyler Kristoff; Jesse Gilbert; Sayoko E Moroi; Arthur J Sit Journal: Am J Ophthalmol Date: 2019-02-19 Impact factor: 5.258
Authors: Inge J M Slenter; Sylvia C Djajadiningrat-Laanen; Daphne J Elders; Reinoud de Gee; Linda E Koele; Loes W Vermeer; Michael H Boevé Journal: Vet Ophthalmol Date: 2019-05-17 Impact factor: 1.644
Authors: Carol B Toris; Shan Fan; Thomas V Johnson; Lucinda J Camras; Cassandra L Hays; Hong Liu; Bruce M Ishimoto Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Anselm Jünemann; Bettina Hohberger; Jürgen Rech; Ahmed Sheriff; Qin Fu; Ursula Schlötzer-Schrehardt; Reinhard Edmund Voll; Sabine Bartel; Hubert Kalbacher; Johan Hoebeke; Robert Rejdak; Folkert Horn; Gerd Wallukat; Rudolf Kunze; Martin Herrmann Journal: Front Immunol Date: 2018-02-12 Impact factor: 7.561
Authors: Anastasios G Konstas; Leopold Schmetterer; Andreas Katsanos; Cindy M L Hutnik; Gábor Holló; Luciano Quaranta; Miguel A Teus; Hannu Uusitalo; Norbert Pfeiffer; L Jay Katz Journal: Adv Ther Date: 2020-10-27 Impact factor: 3.845